The PD-L1 expression levels were also positively correlated with the m6Sig score (r = 0.75, p < 0.0001, Figure 5F), suggesting that melanoma patients may also benefit from the m6Sig score system for PD1/PD-L1 treatment regimens. This evidence concerns the gene PDCD1 and melanoma.